ASCO 2018 Breast Cancer updates. June 29 th 2018 Einav Gal-Yam Sheba MC
|
|
|
- Henry Phillips
- 5 years ago
- Views:
Transcription
1 ASCO 2018 Breast Cancer updates June 29 th 2018 Einav Gal-Yam Sheba MC
2 Early BC
3 Adjuvant Chemotherapy benefit in HR-pos Nneg BC TAILORX
4 Slide 1 Presented By Joseph Sparano at 2018 ASCO Annual Meeting
5 TAILORx Presented By Lisa Carey at 2018 ASCO Annual Meeting
6 TAILORx Randomized Trial Presented By Lisa Carey at 2018 ASCO Annual Meeting
7 What We Knew Already: <br />RS < 11 has Great Prognosis with ET alone Presented By Lisa Carey at 2018 ASCO Annual Meeting
8 Primary Endpoint: idfs in 7.5y Presented By Lisa Carey at 2018 ASCO Annual Meeting
9 Slide 12 Presented By Joseph Sparano at 2018 ASCO Annual Meeting
10 Interesting Exploratory<br />Analyses<br />Randomized <br />Arms Presented By Lisa Carey at 2018 ASCO Annual Meeting
11 Slide 14 Presented By Joseph Sparano at 2018 ASCO Annual Meeting
12 Interesting Exploratory<br />Analyses Presented By Lisa Carey at 2018 ASCO Annual Meeting
13 TAILORx Results: Summary Presented By Joseph Sparano at 2018 ASCO Annual Meeting
14 How Does This Affect Practice Tomorrow?<br />(for node-negative patients appropriate for chemo) Presented By Lisa Carey at 2018 ASCO Annual Meeting
15 Endocrine therapy in premenopausal women ASTRRA SOFT/TEXT updates
16 Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: the ASTRRA study Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
17 Disease free survival (Primary Endpoint) Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
18 Overall Survival (Secondary Endpoint) Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
19 Slide 1 Presented By Meredith Regan at 2018 ASCO Annual Meeting
20 Premenopausal Adjuvant Endocrine Therapy Presented By Meredith Regan at 2018 ASCO Annual Meeting
21 Slide 7 Presented By Meredith Regan at 2018 ASCO Annual Meeting
22 Presented By Meredith Regan at 2018 ASCO Annual Meeting
23 Presented By David Cameron at 2018 ASCO Annual Meeting
24 Duration of adjuvant Trastuzumab
25 PERSEPHONE: 6 versus 12 months of adjuvant trastuzumab in patients with HER2 positive early breast cancer: Randomised phase 3 non-inferiority trial with definitive 4-year disease-free survival results Presented By Helena Earl at 2018 ASCO Annual Meeting
26 Persephone Study Design Presented By Helena Earl at 2018 ASCO Annual Meeting
27 Disease-free survival Presented By Helena Earl at 2018 ASCO Annual Meeting
28 DFS:<br /><br />Pre-defined subgroup analysis Presented By Helena Earl at 2018 ASCO Annual Meeting
29 Overall survival Presented By Helena Earl at 2018 ASCO Annual Meeting
30 OS:<br /><br />Pre-defined subgroup analysis Presented By Helena Earl at 2018 ASCO Annual Meeting
31 Cardiotoxicity However, only 1 time point was examined for the 12 m patients Presented By Helena Earl at 2018 ASCO Annual Meeting
32 Slide 20 Presented By Martine Piccart-Gebhart at 2018 ASCO Annual Meeting
33
34 Slide 22 Presented By Martine Piccart-Gebhart at 2018 ASCO Annual Meeting
35 Slide 23 Presented By Martine Piccart-Gebhart at 2018 ASCO Annual Meeting
36 Slide 25 Conclusions: Further work needed to reliably identify subgroup for which shorter durations could become SOC. Research is mostly directed at de escalating chemotherapy. (Taxane only fared better with 12 m). Reassure patients that need to stop trastuzumab d/t various reasons ( cardiotoxicity, financial toxicity). Unknown interaction with the expanded use of Pertuzumab. Presented By Martine Piccart-Gebhart at 2018 ASCO Annual Meeting
37 BRCA Mutation Carriers
38 Neoadjuvant Talazoparib for Early Stage Breast Cancer Patients with a BRCA Mutation Presented By Jennifer Litton at 2018 ASCO Annual Meeting
39 Study Design Presented By Jennifer Litton at 2018 ASCO Annual Meeting
40 Slide 6 Presented By Martine Piccart-Gebhart at 2018 ASCO Annual Meeting
41 Slide 7 Presented By Martine Piccart-Gebhart at 2018 ASCO Annual Meeting
42 Toxicities Hematologic Presented By Jennifer Litton at 2018 ASCO Annual Meeting
43 Presented By Martine Piccart-Gebhart at 2018 ASCO Annual Meeting
44 Slide 8 Presented By Martine Piccart-Gebhart at 2018 ASCO Annual Meeting
45 Metastatic BC
46 HR positive CDK4 inh
47 Ribociclib + fulvestrant in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from MONALEESA-3 Presented By Dennis Slamon at 2018 ASCO Annual Meeting
48 MONALEESA-3: Phase III placebo-controlled study of ribociclib + fulvestrant Presented By Dennis Slamon at 2018 ASCO Annual Meeting
49 Slide 11 Presented By Dennis Slamon at 2018 ASCO Annual Meeting
50 PFS by prior endocrine therapy status Presented By Dennis Slamon at 2018 ASCO Annual Meeting
51 First line setting Presented By Angela DeMichele at 2018 ASCO Annual Meeting
52 Progression after endocrine therapy Presented By Angela DeMichele at 2018 ASCO Annual Meeting
53 Active in premenopausal patients, regardless of endocrine therapy used Presented By Angela DeMichele at 2018 ASCO Annual Meeting
54 PI3K-AKT-MTOR pathway inhibition
55 Breast cancer and PI3K/AKT pathway Presented By Rebecca Dent at 2018 ASCO Annual Meeting
56 PIK3CA inhibition SANDPIPER Presented By Cynthia Ma at 2018 ASCO Annual Meeting
57 SANDPIPER Efficacy Data Presented By Cynthia Ma at 2018 ASCO Annual Meeting
58 Slide 11 Presented By Cynthia Ma at 2018 ASCO Annual Meeting
59 Slide 12 Presented By Cynthia Ma at 2018 ASCO Annual Meeting
60 Take Home from SANDPIPER: Presented By Cynthia Ma at 2018 ASCO Annual Meeting
61 AKT inhibition ( triple negative) Presented By Rebecca Dent at 2018 ASCO Annual Meeting
62 LOTUS (NCT ) randomized phase II trial Presented By Rebecca Dent at 2018 ASCO Annual Meeting
63 Primary analysis: IPAT effect on PFS enhanced in PIK3CA/AKT1/PTEN-altered subgroup (Foundation Medicinea) Presented By Rebecca Dent at 2018 ASCO Annual Meeting
64 HR:0.62 OS in the ITT population Presented By Rebecca Dent at 2018 ASCO Annual Meeting
65 Updated safety: Most commona adverse events (all grades) Presented By Rebecca Dent at 2018 ASCO Annual Meeting
66 PAKT:<br />A randomised, double-blind, placebo-controlled, phase II trial Presented By Cynthia Ma at 2018 ASCO Annual Meeting
67 PAKT: Presented By Cynthia Ma at 2018 ASCO Annual Meeting
68 Slide 20 Presented By Cynthia Ma at 2018 ASCO Annual Meeting
69 AKT inhibitor in TNBC Presented By Cynthia Ma at 2018 ASCO Annual Meeting
70 Antibody Drug Conjugates
71 Efficacy of sacituzumab govitecan (anti-trop-2-sn-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2 negative metastatic breast cancer (mbc) Presented By Aditya Bardia at 2018 ASCO Annual Meeting
72 Immu-132 Sacituzumab Govitecan <br />Antibody-Drug Conjugate (ADC) Presented By Aditya Bardia at 2018 ASCO Annual Meeting
73 Single-Arm, Open-Label Study Design Presented By Aditya Bardia at 2018 ASCO Annual Meeting
74 Tumor Response to Sacituzumab Govitecan Presented By Aditya Bardia at 2018 ASCO Annual Meeting
75 Response Onset and Durability (N=17) Presented By Aditya Bardia at 2018 ASCO Annual Meeting
76 Response to Sacituzumab Govitecan in Subgroups Presented By Aditya Bardia at 2018 ASCO Annual Meeting
77 Adverse Events (Regardless of Causality) <br />All events >20% or Grade 3+ >5% Presented By Aditya Bardia at 2018 ASCO Annual Meeting
78 Slide 16 Presented By Aditya Bardia at 2018 ASCO Annual Meeting
79
80
81 Utidelone plus capecitabine vs capecitabine for anthracycline- and taxane-refractory MBC Presented By Binghe Xu at 2018 ASCO Annual Meeting
82 Flow Chart for BG L Presented By Binghe Xu at 2018 ASCO Annual Meeting
83 PFS per IRRC FAS Presented By Binghe Xu at 2018 ASCO Annual Meeting
84 Slide 12 Presented By Binghe Xu at 2018 ASCO Annual Meeting
85 Conclusions Presented By Binghe Xu at 2018 ASCO Annual Meeting
86 Adjuvant Denosumab
87 EBCTCG Meta-analyses of Adjuvant bisphosphonate treatment in early breast cancer: The Lancet Volume 386, Issue 10001, Pages Presented By David Cameron at 2018 ASCO Annual Meeting
88 Denosumab Presented By David Cameron at 2018 ASCO Annual Meeting
89 Adjuvant Denosumab In Early Breast Cancer First Results From The International Multicenter Randomized Phase III Placebo-controlled D-CARE Study Presented By Robert Coleman at 2018 ASCO Annual Meeting
90 D-CARE Study Design Presented By Robert Coleman at 2018 ASCO Annual Meeting
91 Presented By Robert Coleman at 2018 ASCO Annual Meeting 40% of the primary end points were deaths
92 Exploratory Endpoints Presented By Robert Coleman at 2018 ASCO Annual Meeting
93 Osteonecrosis Of Jaw (ONJ) Presented By Robert Coleman at 2018 ASCO Annual Meeting
94 Conclusions Presented By Robert Coleman at 2018 ASCO Annual Meeting
95 Key points Presented By David Cameron at 2018 ASCO Annual Meeting
96 Slide 7 Presented By David Cameron at 2018 ASCO Annual Meeting
97 Slide 1 Presented By Michael Gnant at 2018 ASCO Annual Meeting
98 Slide 3 Presented By Michael Gnant at 2018 ASCO Annual Meeting
99 Slide 4 Presented By Michael Gnant at 2018 ASCO Annual Meeting
100 Slide 7 Presented By Michael Gnant at 2018 ASCO Annual Meeting
101 Slide 14 Presented By Michael Gnant at 2018 ASCO Annual Meeting
102 Slide 16 Presented By Michael Gnant at 2018 ASCO Annual Meeting
103 Slide 20 Presented By Michael Gnant at 2018 ASCO Annual Meeting
104 Slide 8 Presented By David Cameron at 2018 ASCO Annual Meeting
105 Key points Presented By David Cameron at 2018 ASCO Annual Meeting
106 Conclusions Presented By David Cameron at 2018 ASCO Annual Meeting
Claudio Zamagni Milano 16 giugno 2018 AIOM Post-ASCO BREAST CANCER HIGHLIGHTS ASCO 2018
Claudio Zamagni Milano 16 giugno 2018 AIOM Post-ASCO BREAST CANCER HIGHLIGHTS ASCO 2018 (Neo)Adjuvant Advanced De-escalation ER+ve HER2 ve Node ve TAILORx HER2 +ve Persephone PerElisa PARPi in gbrcam HER2
Update on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
Advances in Breast Cancer ASCO 2018
Advances in Breast Cancer ASCO 2018 Wylie Hosmer, MD Hartford Healthcare Cancer Institute Special Thanks to Dawn Holcombe for help with slide preparation TAILORx ASCO Highlights HER2 6 vs 12 Long Term
Sesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
The TAILORx Trial: A review of the data and implications for practice
The TAILORx Trial: A review of the data and implications for practice Angela DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology University
Highlights of. Metastatic & Advanced Breast Cancer
Highlights of Metastatic & Advanced Breast Cancer 1 Financial Disclosure(s) I currently have or have had the following relevant financial relations to disclose: Speaker s Bureau: Novartis 2 Off Label Use
ASCO 2018 Breast Cancer Highlights
ASCO 2018 Breast Cancer Highlights Angie DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology Co-Leader, Breast Cancer Program, Abramson
Breast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
Update mbc. endokrine Therapie
Update mbc endokrine Therapie HR neg ER pos Endokrine Resistenz Endokrine Therapie 1 st line Postmenopause AI/Tam/Fulvestrant 84% AI+ Fulvestrant 33% AI (Tam) + Everolimus 84% AI + CDK4/6 92% Prämenopause
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
Triple Negative Breast Cancer
GASCO 2016 San Antonio Breast Cancer Symposium Review Triple Negative Breast Cancer Amelia Zelnak, MD, MSc Atlanta Cancer Care Northside Hospital Cancer Institute Disclosures: consultant for Novartis,
Multimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
Systemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
A vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
Updates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
Metastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
ASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
New Approaches in Breast Cancer Treatment. Tamara Shenkier, MDCM, FRCPC Medical Oncologist, BC Cancer, Vancouver
New Approaches in Breast Cancer Treatment Tamara Shenkier, MDCM, FRCPC Medical Oncologist, BC Cancer, Vancouver Disclosures Advisory board/honorarium (commercial): Genomic Health NanoString Clinical trial
Early Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
Advances in the Diagnosis and Treatment of Breast Cancer. Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD
Advances in the Diagnosis and Treatment of Breast Cancer Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD Disclosures Genomic Health: Speaker and Consultant AstraZeneca:
Overcoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
San Antonio Breast Cancer Symposium December 5-9, 2017
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, as 3rd-line Therapeutic Option for Patients With Relapsed/Refractory Metastatic Triple-Negative Breast Cancer (mtnbc): Efficacy
4, :00 PM 9:00 PM
Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer Robert W Carlson, MD John Crown, MD Charles E Geyer
Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer
Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer Wednesday, December 11, 2013 7:30 PM 9:30 PM San Antonio,
Targeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
Progress in the management of metastatic breast cancer in 2018: Is a cure in the horizon?
Progress in the management of metastatic breast cancer in 2018: Is a cure in the horizon? By Gerardo Colón-Otero, MD Mayo Clinic Florida Address correspondence to: Gerardo Colón-Otero, MD Professor of
Adjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
St Gallen 2017 controversies & consensus
St Gallen 2017 controversies & consensus Shani Paluch-Shimon, MBBS, MSc Head, Breast Cancer Service for Young Women Breast Unit, Division of Oncology Sheba Medical Centre June 2017 St Gallen 2017 De-escalation
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
Systemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016 Yes! Age disparities vary by tumor subtype Genomic risk prediction data in young women Adjuvant systemic therapy
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
Adjuvant bisphosphonates: our recommendations
Adjuvant bisphosphonates: our recommendations Andreas Makris Mount Vernon Cancer Centre OPTIMA launch meeting, 27 April 2017 Breast Cancer Metastasis Tumour cell colonisation of bone Tumour cell proliferation
Systemic Management of Breast Cancer
Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of
New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
Science-Based Innovation-Focused ADC Company. Corporate Overview June 2018
Science-Based Innovation-Focused ADC Company Corporate Overview June 2018 Forward-Looking Statements This presentation, in addition to historical information, contains certain forwardlooking statements
2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
Evolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
Cancers du Sein Métastatiques
Cancers du Sein Métastatiques Véronique Diéras Journée Laurence Leroyer Rennes 18 mai 2018 Plan ESME Inhibiteurs CDK 4/6 RH+ Inhibiteurs PARP Anticorps drogue-conjugués Perspectives 2018-2019 ESME Time
José Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
LA MALATTIA METASTATICA. La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O.
LA MALATTIA METASTATICA La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O. Narni-Amelia (TR) Outline Re-testing metastatic disease Chemo- vs endocrine-therapy
Post-ESMO 2012: Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich T.Rordorf, SAMO Luzern 1
Post-ESMO 2012: Breast Cancer Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich 1 Neoadjuvant treatment (in Her-2 positive disease) neoadjuvant trials abstracts: breast sparing surgery, biomarkers,
Metastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
Disease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
Role of Primary Resection for Patients with Oligometastatic Disease
GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko
Considerations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
Karcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
Outline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
When is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
Roohi Ismail-Khan, MD, MS
Roohi Ismail-Khan, MD, MS Associate Member Department of Breast Oncology H. Lee Moffitt Cancer Center Associate Professor University of South Florida Department of Oncological Sciences September 27, 2018
Update in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
BREAST CANCER RISK REDUCTION (PREVENTION)
BREAST CANCER RISK REDUCTION (PREVENTION) Articles Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled
DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA
Recent Advances of Docetaxel in Management of Breast Cancer DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA 1 ADJUVANT
Science-Based Innovation-Focused ADC Company. Corporate Overview August 2018
Science-Based Innovation-Focused ADC Company Corporate Overview August 2018 Forward-Looking Statements This presentation, in addition to historical information, contains certain forwardlooking statements
Dennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon
Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon In 25 results of 4 Adjuvant Herceptin trials have definitively
ESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer
ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of
XII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
PI3K/AKT/mTOR Inhibitors in Breast Cancer
PI3K/AKT/mTOR Inhibitors in Breast Cancer Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Global Breast Cancer Conference 2015 Outline Overview of PI3K/Akt/mTOR Pathway Rationale
Breast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
Recent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
Case #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer
Case #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer Fellow Presenter: Katherine Clifton, MD Faculty Discussant: Debu Tripathy, MD 7 th Annual June 1, 2018 Topics to Be Discussed: Staging
Post-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
Breast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
14,30 18,20. II Sessione. Moderatori: Giovanni Apolone, Roberto Labianca
14,30 18,20 II Sessione Moderatori: Giovanni Apolone, Roberto Labianca 14,30 14,50 Ca mammario: attualità e prospettive di ricerca Luca Livraghi Carcinoma mammario: attualità e prospettive di ricerca LUCA
Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration
Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration of endocrine therapy 4. Advances in HER2 directed
The Expert Thoughts. Alessandra Fabi Oncologia Medica 1
The Expert Thoughts Alessandra Fabi Oncologia Medica 1 My Thoughts Neoadjuvant: from the lessons of the history Adjuvant: Escalation and De-escalation Advanced and HER2+ : field for immunomodulation Brain
Endocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
Collaborative Management of Patients With Advanced Estrogen Receptor Positive Breast Cancer
Collaborative Management of Patients With Advanced Estrogen Receptor Positive Breast Cancer Lee Schwartzberg, MD, FACP Heather Greene, FNP, AOCNP West Cancer Center Memphis, Tennessee Learning Objectives
The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
Mechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
XII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar Paradigm shift? The Food and Drug Administration collaborative project P. Cortazar, Silver Spring, USA FDA Perspective: Moving from Adjuvant to Neoadjuvant Trials in
Treatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
OUTLINE PAST PRESENTFUTURE BREAST CANCER INCIDENCE AND MORTALITY CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM
OUTLINE CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM October 11, 2014 SARA M GARRIDO, M.D., F.A.C.P Chief Medical Officer at AMS Miami, October 11, 2014 PAST PRESENTFUTURE -BRIEF
PIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
Update on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
Treatment of Metastatic TRIPLE NEGATIVE BREAST CANCERS. Rebecca Dent, MD FRCP (Canada) Senior Consultant, Medical Oncology
Treatment of Metastatic TRIPLE NEGATIVE BREAST CANCERS Rebecca Dent, MD FRCP (Canada) Senior Consultant, Medical Oncology Overview of TNBC Still best way to define in clinical practice!? Survival (%) Treatment
William J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
Endocrine Therapy in Breast Cancer: State of the Art
Endocrine Therapy in Breast Cancer: State of the Art 12 AUG 2018 Mark Pegram, M.D. Susy Yuan-Huey Hung Professor of Oncology Associate Director for Clinical Research Director, Stanford Breast Oncology
EARLY BREAST CANCER, HER2-POSITIVE
EARLY BREAST CANCER, HER2-POSITIVE CLINICAL CASE DISCUSSION Elżbieta Senkus Medical University of Gdańsk Gdańsk, Poland esmo.org DISCLOSURES Honoraria: Amgen, Astellas, AstraZeneca, Bayer, BMS, Celgene,
The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive